FOLFIRI
FOLFIRI 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Ras-mutated Metastatic Colorectal Cancer、mCRC、MSS Metastatic Colorectal Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Oncolytics Biotech
- National Cancer Institute, Naples
- Chinese PLA General Hospital
- Shanghai 6th People's Hospital
- Rutgers, The State University of New Jersey
- Michael J Cavnar, MD
- Shanghai Pudong Hospital
- Sun Yat-sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
意大利、中国、美国、Puerto Rico、South Korea、澳大利亚、加拿大、丹麦、德国、Poland、西班牙、中国台湾
正在招募患者的 FOLFIRI 研究
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
III 期招募中意大利NCT06509126Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
II 期招募中中国NCT07391618A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
II 期招募中中国NCT06590259sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
II 期招募中美国NCT07201519Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
II 期招募中中国NCT07106034A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
III 期招募中中国NCT03303495A Study of ASP1002 in Adults for Treatment of Solid Tumors
I 期招募中美国NCT05719558Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
III 期招募中美国Puerto RicoNCT07702032Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
II 期招募中中国NCT06856187Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
III 期招募中South KoreaNCT05534087A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
I 期招募中美国澳大利亚加拿大丹麦NCT04929223Induction Chemotherapy for Locally Recurrent Rectal Cancer
III 期招募中比利时荷兰挪威PortugalNCT04389086Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
II 期招募中美国NCT04205968The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
I 期 / II 期招募中中国台湾NCT07204574A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
I 期 / II 期招募中美国比利时加拿大中国NCT05379595A Clinical Study of Arfolitixorin in Patients With mCRC
I 期 / II 期招募中德国NCT06922383A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
I 期招募中美国NCT07458347Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)
II 期招募中挪威NCT06907342Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
III 期招募中法国NCT06197425Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy
III 期招募中荷兰NCT06857773Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
II 期招募中中国NCT06176885A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
I 期招募中美国澳大利亚比利时加拿大NCT06179160Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
III 期招募中美国NCT05863195
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。